ID

21386

Description

Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00391560

Lien

https://clinicaltrials.gov/show/NCT00391560

Mots-clés

Versions (1)
  1. 18/04/2017 18/04/2017 -
Téléchargé le

18 avril 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Leukemia NCT00391560

Anglais

Eligibility Leukemia NCT00391560

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00391560
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have relapsed/refractory leukemias for which no standard therapies are anticipated to result in a durable remission. patients with poor-risk myelodysplasia (mds) [i.e. refractory anemia with excess blasts (raeb-1 or raeb-2) by who classification] and chronic myelomonocytic leukemia (cmml) are also candidates for this protocol. relapsed/refractory leukemias include acute non-lymphocytic leukemia (aml) by who classification, acute lymphocytic leukemia (all), chronic lymphocytic leukemia (cll), or chronic myelogenous leukemia (cml) in blast crisis. patients with agnogenic myeloid metaplasia (amm) are also eligible.
Description

Leukemia Recurrent | Leukemia refractory | Standard therapy Remission Durable | Myelodysplasia Low Risk | Refractory anaemia with excess blasts | Refractory anemia with excess blasts II | Leukemia, Myelomonocytic, Chronic | Acute Myelocytic Leukemia WHO tumor classification | Acute lymphocytic leukemia | Chronic Lymphocytic Leukemia | Blast Phase | Primary Myelofibrosis

Type de données

boolean

Alias
UMLS CUI [1,1]
C0023418
UMLS CUI [1,2]
C2945760
UMLS CUI [2,1]
C0023418
UMLS CUI [2,2]
C0205269
UMLS CUI [3,1]
C2936643
UMLS CUI [3,2]
C0544452
UMLS CUI [3,3]
C0449238
UMLS CUI [4,1]
C0026985
UMLS CUI [4,2]
C3538919
UMLS CUI [5]
C0002894
UMLS CUI [6]
C1318551
UMLS CUI [7]
C0023480
UMLS CUI [8,1]
C0023467
UMLS CUI [8,2]
C1301142
UMLS CUI [9]
C0023449
UMLS CUI [10]
C0023434
UMLS CUI [11]
C0005699
UMLS CUI [12]
C0001815
ecog performance status of 0-2
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
sexually active men and women who are not surgically sterile or post menopausal must use acceptable contraceptive methods (physician will discuss acceptable methods) during the time on study and for 4 weeks following the completion of treatment. women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this trial.
Description

Sexually active Contraceptive methods | Female Sterilization | Postmenopausal state | Male sterilization | Childbearing Potential Serum pregnancy test negative | Childbearing Potential Urine pregnancy test negative | Premenopausal state

Type de données

boolean

Alias
UMLS CUI [1,1]
C0241028
UMLS CUI [1,2]
C0700589
UMLS CUI [2]
C0015787
UMLS CUI [3]
C0232970
UMLS CUI [4]
C0024559
UMLS CUI [5,1]
C3831118
UMLS CUI [5,2]
C0430061
UMLS CUI [6,1]
C3831118
UMLS CUI [6,2]
C0430057
UMLS CUI [7]
C0232969
in the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents, or at least five half-lives for noncytotoxic agents. persistent chronic toxicities from prior chemotherapy must not be greater than grade 1.
Description

Disease Rapidly progressive Absent | Cytotoxic agent | Non-Cytotoxic Agent | Chemotherapy | Toxicity chronic persistent CTCAE Grades

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1838681
UMLS CUI [1,3]
C0332197
UMLS CUI [2]
C0304497
UMLS CUI [3]
C2827065
UMLS CUI [4]
C0392920
UMLS CUI [5,1]
C0600688
UMLS CUI [5,2]
C0205191
UMLS CUI [5,3]
C0205322
UMLS CUI [5,4]
C1516728
patients must have the following clinical laboratory values:
Description

Laboratory Results

Type de données

boolean

Alias
UMLS CUI [1]
C1254595
serum creatinine: <= 2.0 mg/dl
Description

Creatinine measurement, serum

Type de données

boolean

Alias
UMLS CUI [1]
C0201976
total bilirubin: <=1.5x the upper limit of normal unless considered due to gilbert's syndrome
Description

Serum total bilirubin measurement | Serum total bilirubin measurement Due to Gilbert Disease

Type de données

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2,1]
C1278039
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0017551
alanine aminotransferase (alt), or aspartate aminotransferase (ast): <= 3x the upper limit of normal unless considered due to organ leukemic involvement
Description

Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement Due to Organ involvement Leukemia | Aspartate aminotransferase measurement Due to Organ involvement Leukemia

Type de données

boolean

Alias
UMLS CUI [1]
C0201836
UMLS CUI [2]
C0201899
UMLS CUI [3,1]
C0201836
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C0457576
UMLS CUI [3,4]
C0023418
UMLS CUI [4,1]
C0201899
UMLS CUI [4,2]
C0678226
UMLS CUI [4,3]
C0457576
UMLS CUI [4,4]
C0023418
must be able and willing to give written informed consent
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
age equal to or greater than 18 years
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Description

Comorbidity Uncontrolled | Communicable Disease Uncontrolled | Symptomatic congestive heart failure | Cardiac Arrhythmia | Mental disorder Protocol Compliance Limited | Social situation Protocol Compliance Limited

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205318
UMLS CUI [3]
C0742758
UMLS CUI [4]
C0003811
UMLS CUI [5,1]
C0004936
UMLS CUI [5,2]
C0525058
UMLS CUI [5,3]
C0439801
UMLS CUI [6,1]
C0748872
UMLS CUI [6,2]
C0525058
UMLS CUI [6,3]
C0439801
active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure
Description

Heart Disease | Myocardial Infarction | Coronary Artery Disease Symptomatic | Cardiac Arrhythmia Uncontrolled | Congestive heart failure Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0027051
UMLS CUI [3,1]
C1956346
UMLS CUI [3,2]
C0231220
UMLS CUI [4,1]
C0003811
UMLS CUI [4,2]
C0205318
UMLS CUI [5,1]
C0018802
UMLS CUI [5,2]
C0205318
patients with a history of severe hyper-reactive airway system (e.g. active asthma, copd)
Description

Hyperreactive airway disease Severe | Asthma | Chronic Obstructive Airway Disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C0340062
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C0004096
UMLS CUI [3]
C0024117
patients receiving any other standard or investigational treatment for their hematologic malignancy
Description

Standard therapy Hematologic Neoplasm | Investigational Therapy Hematologic Neoplasm

Type de données

boolean

Alias
UMLS CUI [1,1]
C2936643
UMLS CUI [1,2]
C0376545
UMLS CUI [2,1]
C0949266
UMLS CUI [2,2]
C0376545
pregnant and nursing patients are excluded because the effects of perifosine on a fetus or nursing child are unknown.
Description

Pregnancy | Breast Feeding | perifosine

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0754570
Retour au début de la page

Similar models

Eligibility Leukemia NCT00391560

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00391560
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Leukemia Recurrent | Leukemia refractory | Standard therapy Remission Durable | Myelodysplasia Low Risk | Refractory anaemia with excess blasts | Refractory anemia with excess blasts II | Leukemia, Myelomonocytic, Chronic | Acute Myelocytic Leukemia WHO tumor classification | Acute lymphocytic leukemia | Chronic Lymphocytic Leukemia | Blast Phase | Primary Myelofibrosis
Item
patients must have relapsed/refractory leukemias for which no standard therapies are anticipated to result in a durable remission. patients with poor-risk myelodysplasia (mds) [i.e. refractory anemia with excess blasts (raeb-1 or raeb-2) by who classification] and chronic myelomonocytic leukemia (cmml) are also candidates for this protocol. relapsed/refractory leukemias include acute non-lymphocytic leukemia (aml) by who classification, acute lymphocytic leukemia (all), chronic lymphocytic leukemia (cll), or chronic myelogenous leukemia (cml) in blast crisis. patients with agnogenic myeloid metaplasia (amm) are also eligible.
boolean
C0023418 (UMLS CUI [1,1])
C2945760 (UMLS CUI [1,2])
C0023418 (UMLS CUI [2,1])
C0205269 (UMLS CUI [2,2])
C2936643 (UMLS CUI [3,1])
C0544452 (UMLS CUI [3,2])
C0449238 (UMLS CUI [3,3])
C0026985 (UMLS CUI [4,1])
C3538919 (UMLS CUI [4,2])
C0002894 (UMLS CUI [5])
C1318551 (UMLS CUI [6])
C0023480 (UMLS CUI [7])
C0023467 (UMLS CUI [8,1])
C1301142 (UMLS CUI [8,2])
C0023449 (UMLS CUI [9])
C0023434 (UMLS CUI [10])
C0005699 (UMLS CUI [11])
C0001815 (UMLS CUI [12])
ECOG performance status
Item
ecog performance status of 0-2
boolean
C1520224 (UMLS CUI [1])
Sexually active Contraceptive methods | Female Sterilization | Postmenopausal state | Male sterilization | Childbearing Potential Serum pregnancy test negative | Childbearing Potential Urine pregnancy test negative | Premenopausal state
Item
sexually active men and women who are not surgically sterile or post menopausal must use acceptable contraceptive methods (physician will discuss acceptable methods) during the time on study and for 4 weeks following the completion of treatment. women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this trial.
boolean
C0241028 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0015787 (UMLS CUI [2])
C0232970 (UMLS CUI [3])
C0024559 (UMLS CUI [4])
C3831118 (UMLS CUI [5,1])
C0430061 (UMLS CUI [5,2])
C3831118 (UMLS CUI [6,1])
C0430057 (UMLS CUI [6,2])
C0232969 (UMLS CUI [7])
Disease Rapidly progressive Absent | Cytotoxic agent | Non-Cytotoxic Agent | Chemotherapy | Toxicity chronic persistent CTCAE Grades
Item
in the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents, or at least five half-lives for noncytotoxic agents. persistent chronic toxicities from prior chemotherapy must not be greater than grade 1.
boolean
C0012634 (UMLS CUI [1,1])
C1838681 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0304497 (UMLS CUI [2])
C2827065 (UMLS CUI [3])
C0392920 (UMLS CUI [4])
C0600688 (UMLS CUI [5,1])
C0205191 (UMLS CUI [5,2])
C0205322 (UMLS CUI [5,3])
C1516728 (UMLS CUI [5,4])
Laboratory Results
Item
patients must have the following clinical laboratory values:
boolean
C1254595 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine: <= 2.0 mg/dl
boolean
C0201976 (UMLS CUI [1])
Serum total bilirubin measurement | Serum total bilirubin measurement Due to Gilbert Disease
Item
total bilirubin: <=1.5x the upper limit of normal unless considered due to gilbert's syndrome
boolean
C1278039 (UMLS CUI [1])
C1278039 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0017551 (UMLS CUI [2,3])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement Due to Organ involvement Leukemia | Aspartate aminotransferase measurement Due to Organ involvement Leukemia
Item
alanine aminotransferase (alt), or aspartate aminotransferase (ast): <= 3x the upper limit of normal unless considered due to organ leukemic involvement
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0457576 (UMLS CUI [3,3])
C0023418 (UMLS CUI [3,4])
C0201899 (UMLS CUI [4,1])
C0678226 (UMLS CUI [4,2])
C0457576 (UMLS CUI [4,3])
C0023418 (UMLS CUI [4,4])
Informed Consent
Item
must be able and willing to give written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
age equal to or greater than 18 years
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Comorbidity Uncontrolled | Communicable Disease Uncontrolled | Symptomatic congestive heart failure | Cardiac Arrhythmia | Mental disorder Protocol Compliance Limited | Social situation Protocol Compliance Limited
Item
uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0742758 (UMLS CUI [3])
C0003811 (UMLS CUI [4])
C0004936 (UMLS CUI [5,1])
C0525058 (UMLS CUI [5,2])
C0439801 (UMLS CUI [5,3])
C0748872 (UMLS CUI [6,1])
C0525058 (UMLS CUI [6,2])
C0439801 (UMLS CUI [6,3])
Heart Disease | Myocardial Infarction | Coronary Artery Disease Symptomatic | Cardiac Arrhythmia Uncontrolled | Congestive heart failure Uncontrolled
Item
active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure
boolean
C0018799 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
C1956346 (UMLS CUI [3,1])
C0231220 (UMLS CUI [3,2])
C0003811 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0018802 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
Hyperreactive airway disease Severe | Asthma | Chronic Obstructive Airway Disease
Item
patients with a history of severe hyper-reactive airway system (e.g. active asthma, copd)
boolean
C0340062 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0004096 (UMLS CUI [2])
C0024117 (UMLS CUI [3])
Standard therapy Hematologic Neoplasm | Investigational Therapy Hematologic Neoplasm
Item
patients receiving any other standard or investigational treatment for their hematologic malignancy
boolean
C2936643 (UMLS CUI [1,1])
C0376545 (UMLS CUI [1,2])
C0949266 (UMLS CUI [2,1])
C0376545 (UMLS CUI [2,2])
Pregnancy | Breast Feeding | perifosine
Item
pregnant and nursing patients are excluded because the effects of perifosine on a fetus or nursing child are unknown.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0754570 (UMLS CUI [3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial